KH902 fusion protein

Known as: conbercept 
 

Topic mentions per year

Topic mentions per year

2013-2017
024620132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
PURPOSE To confirm the therapeutic efficacy of conbercept for the treatment of macular edema (ME) secondary to branch retinal… (More)
Is this relevant?
2017
2017
The novel anti-VEGF drug conbercept has been used in the treatment of several retinal neovascular diseases. Owning to the… (More)
Is this relevant?
2017
2017
OBJECTIVE To investigate the serum levels of vascular endothelial growth factor (VEGF) before and after intravitreal injection of… (More)
Is this relevant?
2016
2016
PURPOSE To evaluate the role, safety, and effectiveness of intravitreal conbercept (KH902) injections as an adjunct to vitrectomy… (More)
Is this relevant?
2016
2016
PURPOSE To evaluate the efficacy of different doses of conbercept in patients with polypoidal choroidal vasculopathy in the… (More)
Is this relevant?
2016
2016
BACKGROUND Polypoidal choroidal vasculopathy (PCV) is characterized by the presence of polyps with or without a branching… (More)
Is this relevant?
2015
2015
Age-related macular degeneration (AMD) is a progressive, degenerative disease of the retina that occurs with increasing incidence… (More)
Is this relevant?
2015
2015
OBJECTIVE To observe the efficacy and safety of intravitreal injection of conbercept, a new drugs of VEGFR fusion proteins, on… (More)
Is this relevant?
2014
2014
PURPOSE To assess the safety and efficacy of multiple injections of 0.5 and 2.0 mg conbercept using variable dosing regimens in… (More)
Is this relevant?
2013
2013
VEGF family factors are known to be the principal stimulators of abnormal angiogenesis, which play a fundamental role in tumor… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?